Drug Insight: new drugs in development for Parkinson's disease

@article{Colosimo2006DrugIN,
  title={Drug Insight: new drugs in development for Parkinson's disease},
  author={C. Colosimo and Giovanni Fabbrini and Alfredo Berardelli},
  journal={Nature Clinical Practice Neurology},
  year={2006},
  volume={2},
  pages={600-610}
}
For many years, levodopa has given most patients with Parkinson's disease excellent symptomatic benefit. This agent does not slow down the progression of the disease, however, and it can induce motor fluctuations and dyskinesias in the long term. The other available antiparkinsonian agents also have drawbacks, and as a consequence research into antiparkinsonian drugs is expected to take new and different directions in the coming years. The most promising approaches include the development of… CONTINUE READING
5 Citations
83 References
Similar Papers

References

Publications referenced by this paper.
Showing 1-10 of 83 references

A randomized , double - blind , futility clinical trial of creatine and minocycline in early Parkinson disease

  • LJ Currie
  • Neurology
  • 2006

Effects of serotonin 5-HT1A agonist in advanced Parkinson’s disease

  • W Bara-Jimenez
  • Mov Disord
  • 2005

The effects of a selective D2 receptor agonist on behavioral and pathologic outcome in MPTP-treated squirrel monkeys

  • DT Stephenson
  • J Pharmacol Exp Ther
  • 2005

Similar Papers

Loading similar papers…